Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis
Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addres...